Access to health

We have a heritage of improving existing standards of care for chronic diseases. Our commitment extends to people who lack access to treatment, those who face barriers due to inadequate healthcare infrastructures or the high out-of-pocket costs that can be a part of having a progressive, chronic disease.

The primary goal of our long-term efforts is to generate the greatest health impact for patients, protecting the most vulnerable and building partnerships and healthcare system capacity to confront the diabetes pandemic in Least Developed Countries (LDCs) and emerging economies.

As part of our 2009 performance, Novo Nordisk:

  • Donated 84 million Danish kroner to the World Diabetes Foundation and the Novo Nordisk Haemophilia Foundation, supporting sustainable projects to expand healthcare system capacity in the developing world
     
  • Diagnosed more than 400 children with type 1 diabetes in developing countries as part of the Changing Diabetes® in Children programme
     
  • Offered insulin to the world's Least Developed Countries (LDCs) at or below a price of 20% of the average price for insulin in the Western world, as part of our differential pricing policy offering
     
  • Trained or educated 805,000 healthcare professionals and 416,000 people with diabetes
 

Building sustainable partnerships

We work to mobilise awareness of the importance of fighting diabetes. Our approach to access builds on the United Nations (UN) defined cornerstones on the right to health and aligns with the UN Millennium Development Goals, which offer a common vision for tackling some of the major challenges facing the world.


Measuring progress

Setting ambitious objectives and targets and reporting on progress in meeting our goals are core elements of the Novo Nordisk Way of Management. However, we face two major challenges in measuring the impact of efforts to expand access to care. First, we need to develop meaningful and useful indicators for measuring performance in areas where there is yet no corporate precedence for reporting. Second, we need to find ways of dealing with the challenges of obtaining good quality data in regions where monitoring of health care quality is not standard.